在一项随机、对照纳曲酮试验中，阿片受体基因型与戒烟结局之间缺乏关联。
Lack of Association between Opioid-Receptor Genotypes and Smoking Cessation Outcomes in a Randomized, Controlled Naltrexone Trial.
机构信息
Department of Psychiatry, University of Maryland School of Medicine, Baltimore, MD 21201, USA.
Department of Psychological Sciences, University of Missouri, 210 McAlester Hall, Columbia, MO 65211, USA.
出版信息
Alcohol Alcohol. 2019 Jan 9;54(5):559-565. doi: 10.1093/alcalc/agz046.
AIMS
The present study examined how variation in mu- (OPRM1), kappa- (OPRK), and delta- (OPRD) opioid receptor genes may influence the efficacy of naltrexone in the context of a smoking cessation trial.
METHODS
The study's primary objective was to examine the association of the Asn40Asp OPRM1 single nucleotide polymorphism (SNP) with naltrexone's effects on smoking quit rate, weight gain, and heavy drinking behavior during a double-blind, randomized clinical trial in 280 adult DSM-IV nicotine-dependent participants. The secondary goal of the study was to examine the relationship of 20 additional SNPs of OPRM1, OPRK, and OPRD with the aforementioned outcomes.
RESULTS
Results indicated a null association between any opioid-receptor gene SNP and naltrexone's effects on smoking quit rate, weight gain, and heavy drinking behavior in this sample of nicotine dependent participants.
CONCLUSIONS
In sum, these results do not suggest that genetic variation in opioid-receptors is related to treatment responses to naltrexone in a smoking cessation trial.
目的
本研究旨在探讨μ-（OPRM1）、κ-（OPRK）和δ-（OPRD）阿片受体基因的变异如何影响纳曲酮在戒烟试验中的疗效。
方法
该研究的主要目的是在 280 名成年 DSM-IV 尼古丁依赖参与者的双盲、随机临床试验中，检验阿片受体 1（OPRM1）单核苷酸多态性（SNP）Asn40Asp 与纳曲酮对戒烟率、体重增加和重度饮酒行为的影响之间的关联。该研究的次要目标是检验 OPRM1、OPRK 和 OPRD 中 20 个额外 SNP 与上述结果的关系。
结果
结果表明，在这个尼古丁依赖参与者样本中，任何阿片受体基因 SNP 与纳曲酮对戒烟率、体重增加和重度饮酒行为的影响之间均无关联。
结论
总之，这些结果表明，阿片受体基因的遗传变异与戒烟试验中纳曲酮的治疗反应无关。
Zotero 插件